Published DateClear

Start Date

End Date

Category

• Pipeline2

Organizations

• Annexion Inc.2

Tags

• Clinical Trials2
• Geographic Atrophy2
• Retina2
• AMD1
• Injections1

Pipeline

Annexon releases phase 2 and 3 clinical developments for GA therapeutic

New findings from ARCHER and ARCHER II trials support the potential for ANX007 to be the first therapeutic approved for vision protection.

Pipeline

Annexon releases topline data for phase 2 GA study

ARCHER trial is assessing ANX007 as the first complement therapy for preserving visual acuity.